Portrait of Jeffrey Fineman
  • Telehealth visits
bch logo

Jeffrey Fineman, MD

Pediatric Critical CareMedical Director, Pediatric Critical Care
Co-director, Pediatric Heart Center
Portrait of Jeffrey Fineman
Portrait of Jeffrey Fineman
bch logo

Jeffrey Fineman, MD

Pediatric Critical CareMedical Director, Pediatric Critical Care
Co-director, Pediatric Heart Center
  • Telehealth visits

On this page

About me

Dr. Jeffrey Fineman is a pediatric critical care specialist who serves as chief of the pediatric critical care division. He is an associate investigator in the UCSF Cardiovascular Research Institute. His research has focused on diseases related to pulmonary circulation and has led to new therapies for pulmonary hypertension, including a drug called inhaled nitric oxide that was approved by the Food and Drug Administration. His laboratory, funded by the National Institutes of Health, investigates disease processes in the body involved in pulmonary hypertension.

Fineman earned his medical degree at New York University Grossman School of Medicine and completed a residency in pediatrics at NYU Langone Health's Bellevue Hospital Center, serving as chief resident. He completed a fellowship in pediatric critical care medicine at UCSF before joining the staff.

Education & training

Board certification

  • Pediatric Critical Care Medicine, American Board of Pediatrics

Residency

  • Pediatrics, New York University School of Medicine

Internship

  • Pediatrics, New York University School of Medicine

Degree

  • MD, New York University School of Medicine

Academic Title

  • Professor

My expertise

My research

Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.

The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.